Harrow announced that it signed agreements with Santen Pharmaceutical Co. affiliates to acquire their branded ophthalmic portfolio and also with Novaliq GmbH to acquire Vevye.
According to a press release from Harrow, the company will obtain certain commercial rights to Santen’s U.S. products Flarex (fluorometholone acetate ophthalmic suspension) 0.1%, Natacyn (natamycin ophthalmic suspension) 5%, Tobradex ST (tobramycin and dexamethasone ophthalmic suspension) 0.3%/0.05%, Verkazia (cyclosporine ophthalmic emulsion) 0.1%, Zerviate (cetirizine ophthalmic solution) 0.24% and Freshkote; and